Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Octreotide (Sandostatin® LAR®) is recommended as an option for use within NHS Wales for the treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded. |
|||
|
|||
Medicine details |
|||
| Medicine name | octreotide (Sandostatin® LAR®) | ||
| Formulation | 10 mg, 20 mg, and 30 mg powder and solvent for suspension for injection | ||
| Reference number | 3732 | ||
| Indication | Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1518 | ||
| NMG meeting date | 11/07/2018 | ||
| AWMSG meeting date | 12/09/2018 | ||
| Date of issue | 20/09/2018 | ||
| Date of last review | April 2022 | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||